Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
Journal of Clinical Medicine logo

Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation

From the introduction Sepsis is an important and expensive global health problem with high morbidity and mortality. According to the World Health Organization, more than 11 million people die from sepsis worldwide annually—more than the deaths caused by all cancers combined and comprising almost 20% of all deaths annually. Sepsis...
Immunexpress - the signature diagnostics for sepsis

Citeline Podcast: Trio Of Diagnostics Execs Weigh In On Upcoming Challenges

From the Citeline podcast show notes: During this episode, Barnaby Pickering is joined by Rollie Carlson, CEO of Immunexpress, developer of Septicyte, a test for sepsis, Mark McDonough, CEO of ChromaCode, a company developing multiple blood-based tests for cancer diagnosis and treatment, with its first being in non-small cell lung...
Immunexpress - the signature diagnostics for sepsis

Accurate Identification of Sepsis using SeptiCyte® RAPID and Comparison with other Biomarkers Presented at Society of Critical Care Medicine Critical Care Congress 2024

This press release was first published at PR Newswire SEATTLE and BRISBANE, Australia, Jan. 22, 2024 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced  that data validating the use of SeptiCyte® RAPID in differentiating sepsis from systemic inflammatory response syndrome (SIRS) was selected for...
360DX

With Expanded FD A Clearance for Sepsis Test, Immunexpress Furthers Commercialization Strategy

Jan 21, 2024 | Kelsy Ketchum NEW YORK – After getting expanded clearance from the US Food and Drug Administration for its sepsis test, Immunexpress is continuing its commercialization path and working on further expansions for its assay. The qPCR-based SeptiCyte Rapid test first received FDA clearance in 2021 and...
Cision PR Newswire

SeptiCyte RAPID® By Immunexpress Receives Regulatory Clearance from Australian Therapeutic Goods Administration (TGA)

The Cost of Sepsis in Australia report (2021) estimated that there are >90,000 sepsis cases in Australia each year and estimated direct and indirect costs of $700 million and $4 billion respectively SEATTLE and BRISBANE, Australia, Jan. 17, 2024 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on...
360DX

“Immunexpress Nabs 510(k) Clearance for EDTA Blood-Compatible Cartridges”

Via 360Dx, " Jan 04, 2024 | staff reporter NEW YORK – Immunexpress announced Thursday that it has secured US Food and Drug Administration 510(k) clearance for ethylenediaminetetraacetic acid (EDTA) blood-compatible cartridges for use with the firm's SeptiCyte Rapid test to differentiate sepsis from infection-negative systemic inflammation. Read the rest here: 360Dx
Immunexpress.com

Immunexpress Announces U.S. FDA Clearance of EDTA Blood Compatible Cartridges for SeptiCyte RAPID®

EDTA blood collection tubes are used routinely in clinical settings for hematology procedures around the world SEATTLE and BRISBANE, Australia, Jan. 4, 2024 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the clearance of EDTA blood compatible cartridges by...
Carlson - Mastering Medical Device podcast

Rollie Carlson on How Cross-Training and Extreme Ownership Help You Advance Your Career

Immunexpress CEO Rollie Carlson recently appeared on the Mastering Medical Device podcast. Rollie Calrson is the CEO of Immunexpress, a company that is pioneering technology that can rapidly detect sepsis. Rollie contributed to the success of Abbott Laboratories for 20 years, starting off in R&D, then transitioning to leadership positions...
Immunexpress - the signature diagnostics for sepsis

Data Presentation at Association for Molecular Pathology 2023 Validates Performance of SeptiCyte® RAPID in Immunocompromised Patients and Patients on Immunosuppressive Therapy

SeptiCyte® RAPID may aid clinicians in determining early antibiotic administration and in bundle compliance for immunocompromised patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Nov. 17, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation...
Roland Carlson interview for Progress Potential Possibilities

“Improving Outcomes For Patients With Sepsis” — Interview from Progress, Potential & Possibilities

https://www.youtube.com/watch?v=hv-Oy98PA6w "Today we have the honor of being joined by Dr Roland Carlson, who is the Chief Executive Officer of Immuneexpress which is a Seattle-based molecular diagnostic company they're committed to improving the outcomes for patients suspected of having sepsis and their FDA-cleared SeptiCyte technology is focused on rapidly quantifying...
Chart prepared by Cone Health. User-readable PDF version is linked, below.

Chart: Potential impact of a host response gene expression sepsis assay (septicyte rapid) in a tertiary emergency department setting

This chart will be presented by Immunexpress collaborators from Cone Health, Greensboro, NC. at the CHEST Annual Meeting in Honolulu, October on October 10th, 2023. CHEST SeptiCyte Chart for the 2023 CHEST annual meeting (downloadable, screen-readable pdf)
Immunexpress - the signature diagnostics for sepsis

CHEST 2023 Poster Demonstrates the Utility of SeptiCyte® RAPID in Antibiotic Administration and Sepsis Bundle Compliance

This official press release was first published on PRNewswire SeptiCyte® RAPID may aid clinicians in making a determination on early antibiotic administration and in bundle compliance for patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Oct. 2, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis...

If you are a member of the media, please contact:

Scott Stachowiak
Russo Partners
(646) 942-5630
scott.stachowiak@russopartnersllc.com